Session » Sjögren's Syndrome Poster II: Clinical Research

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1484

Association between Primary Sjogren’s Syndrome, Arterial Stiffness and Subclinical Atherosclerosis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1485

Association between Primary Sjogren’s Syndrome, Cardiovascular and Cerebrovascular Events: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1490

Cardiovascular Morbidity and Mortality in Primary Sjögren Syndrome: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1493

Characteristics of Korean Primary Sjogren’s Syndrome and Comparison of 3 Different Classification Criteria for Primary Sjogren’s Syndrome: Data from Korean Kiss Cohort

9:00AM-11:00AM: Abstract Number: 1497

Clinical and Laboratory Features of Patients with Focal Lymphocytic Sialadenitis on Minor Salivary Gland Biopsy for Sicca Symptoms: A 16 Year Experience

9:00AM-11:00AM: Abstract Number: 1502

Comparison of Classification Criteria for Sjögren’s Syndrome from 2002 and 2016 in an Incident Cohort Diagnosed 2007 to 2011 from Stockholm County Sweden

9:00AM-11:00AM: Abstract Number: 1488

Correlation between Lung Ultrasound, HRCT Findings and Pulmonary Function Tests in Primary Sjögren’s Syndrome (pSS)-Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1489

Development and Validation of a Questionnaire to Assess Healthcare Utilization and Access in Cohorts of Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1479

Difference in Clinical Presentation between Female and Male Patients with Primary Sjogren’s Syndrome at Diagnosis and in Long-Term Follow-up

9:00AM-11:00AM: Abstract Number: 1483

Incidence of Cancer in a Cohort of Patients with Primary Sjögren Syndrome

9:00AM-11:00AM: Abstract Number: 1486

Interstitial Lung Disease in Primary Sjögren’s Syndrome : Clinical Presentation, Serological Biomarkers and Long Term Outcome

9:00AM-11:00AM: Abstract Number: 1491

Is There a Seasonal Effect on Fatigue, Pain, and Dryness in Primary Sjögren’s Syndrome? Data from the Prospective Assess Cohort and from 3 Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1498

Long-Term Cohort of Patients with a Clinical Diagnosis of Sjogren’s Syndrome: Activity Index and Patient Reported Outcome Performance

9:00AM-11:00AM: Abstract Number: 1500

Longitudinal Analysis of Different Therapeutic Strategies in Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1495

Longitudinal Changes in EULAR Sjögren’s Syndrome Patient Reported Index in Routine Clinical Practice

9:00AM-11:00AM: Abstract Number: 1499

Major Salivary Gland Ultrasonography Bed-Side and Still Image Scoring – a Pilot Comparison in Juvenile Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1482

Preliminary Population-Based Incidence and Prevalence Estimates of Primary Sjogren’s Syndrome from the Manhattan Lupus Surveillance Program

9:00AM-11:00AM: Abstract Number: 1481

Risk of Ischemic Heart Disease in Sjögren’s Syndrome Patients: A Systematic Review and Meta-Analysis of Observational Studies

9:00AM-11:00AM: Abstract Number: 1480

Risk of Ischemic Stroke in Sjögren’s Syndrome Patients: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1487

Salivary Gland Ultrasonography (SGUS) and Subclinical Parotid Involvement: Usefulness of Sgus in the Identification of a Subset of Patients with Sjögren’s Syndrome at Higher Risk for Extraglandular Disease Manifestations

9:00AM-11:00AM: Abstract Number: 1501

Sexual Dysfunction and Vaginal Dryness Are Common in Female Patients with Early, Active Primary Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1496

The Performance of Different Classification Criteria in Patients with Primary Sjogren’s Syndrome and Analysis of Their Contribution for Definitive Diagnosis, When Either Criteria Used Alone or in Combination

9:00AM-11:00AM: Abstract Number: 1492

Total Body Water Correlates with Ocular Sicca Symptoms in Primary SjöGren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1494

Validation of New Criteria in “The Guidance for Diagnosis of Sjögren’s Syndrome in Pediatric Patients”

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].